However, in a high mutation-prevalence cohort of melanoma patients undergoing a mutation-based follow-up, no differences were found between CDKN2A-positive and CDKN2A-negative patients in terms of OS (HR = 0.85; 95% CI = 0.48–1.52) and MSS (HR = 0.86; 95% CI = 0.38–1.95) [3]. This evidence concerns the gene CDKN2A and melanoma.